Krka, D. D., Novo Mesto · LJSE:KRKG
Krka, D. D., Novo Mesto — Investor Day (November 2025)
24 slides from Krka, D. D., Novo Mesto's investor day presentation, November 2025
Slide 1: KRKA 1-9 2025 Results and Strategy
Krka, d. d., Novo mesto (KRKG SV) KRKA 1-9 2025 Results and Strategy
Slide 2: We stand by you because you need reliable medicines
WE STAND BY YOU BECAUSE YOU NEED RELIABLE MEDICINES
Slide 3: Krka Group Business Performance
Krka Group Business Performance 1-9/2025 business performance highlights SALES 5Y CAGR: 5.8% ✓ Record 1-9 2025 sales: €1,534m; +7% yoy; volume growth: +5% yoy In EUR 1.173 1.242 1.341 1.435 1.534 million ✓ EBITDA margin: 28.5%; EBIT margin: 23.9% 1-9 21 1-9 22 1-9 23 1-9 24 1-9 25 ✓ Record 1-9 2025
Slide 4: Krka Group Sales by Regions
Krka Group Sales by Regions Continuation of robust sales dynamics TOP 5 markets Russian Federation +12% 1-9 2025 sales: EUR 1,529m of goods and 240 251 260 282 315 services (+7% yoy; EUR +101.6m) In EUR million 1-9 21 1-9 22 1-9 23 1-9 24 1-9 25 Overseas Markets Slovenia Poland; +11% -3% EUR 55.1m E
Slide 5: Broad Product Portfolio
Broad Product Portfolio Rx remain the most important product group, with EUR +93m increase yoy Health-resort Majority of sales for & tourist companion animals services +11% Mainly for chronical diseases Animal health products EUR 41.9m; EUR 88.8m; (EUR +2m) +2% (EUR +4m) Prescription 2.8% pharmaceut
Slide 6: Research and Development
Research and Development Committed to continuous development of innovative branded generic products 17 new MA for products & over 790 MA procedures finalised €144m R&D expenses ✓ Dagraduo* (sitagliptin, dapagliflozin) diabetes. Mexdagry & Lynxaram for reliable glycaemic control. Lynxaram* (linaglipt
Slide 7: Krka's Innovative Medicines
Krka’s Innovative Medicines Innovative branded generic producer, with own R&D ADVANCED UNIQUE STATE-OF-THE-ART UNIQUE PHARMACEUTICAL SINGLE PILL EQUIPMENT Delivering the most demanding FORMULATIONS Great possibility of STRENGTHS Tailoring the COMBINATIONS Synergistic action & >150 projects in terms
Slide 8: Investments
Investments Technological enhancement of manufacturing, development activities and quality assurance In the 1-9 2025, the Krka Group allocated EUR 66.7 million for investments, of which EUR 48 million was invested by the controlling company. NOTOL (FDF production & packaging) OPSI (sterile products)
Slide 9: Consolidated Income Statement
Consolidated Income Statement Maintaining high profitability +6% EUR thousand 1-9 2025 (%) 1-9 2024 (%) YoY 1,172,260 Revenue 1,534,028 100 1,434,662 100 7% 1,107,143 Costs of goods sold 649,176 615,339 5% Gross profit 884,852 58 819,323 57 8% 649.176 615.339 Other operating income 5,386 0 5,090 0 6
Slide 10: Krka Group Operating Results
Krka Group Operating Results Maintaining high profitability Profitability Margins development 70% EUR million 1-9 2025 1-9 2024 yoy 57% 57% 57% 57% 58% 60% Gross profit 884.9 819.3 8% 50% Gross profit margin 57.7% 57.1% Average EBITDA margin: 29.2% EBITDA 436.7 401.7 9% 40% EBITDA margin 28.5% 28.0%
Slide 11: FX Impact
FX Impact Positive contribution of RUB in 1-9 2025 EUR/RUB FX rate (2020 –2025) 60 160 The Krka Group‘s net Neto finančni result Net financial izid 140 financial profit, which 30 +28.3m EUR includes FX differences, EURRUB +51.9m EUR +4.7m EUR 120 interest income and EUR / RUB EUR million (1-9 2024)
Slide 12: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position Strong financial position without leverage burden EUR thousand 30.09.2025 (%) 31.12.2024 (%) change change % ASSETS 2,967,622 100 2,849,021 100 118,601 4% Non-current assets 1,048,461 35 1,022,901 36 25,560 2% Current assets 1,919,161 65 1,826,120 64 93,0
Slide 13: Performance Indicators
Performance Indicators Maintaining long-term momentum Revenue in € million EBITDA in € million 600 504 520 554 2.500 464 488 1910 2000 500 2.000 1717 1806 Q3 2025 1565 400 1.500 5y average (2020-2024) Q2 2025 300 EBITDA margin: 29.2% 1.000 200 Q1 2025 1-9 2025 500 5Y CAGR 5.1% 100 5Y CAGR 6.2% Q4 20
Slide 14: Dividend Policy and Share Buyback
Dividend Policy and Share Buyback Management committed to stable capital allocation DPS and dividend yield* for the business year Treasury shares Continually increasing dividend payout policy Repurchasing treasury shares whenever possible 9,00 8% 8% 7.3% 8,00 7% 6,4% 10Y CAGR 14.1% 7,00 5.9% 6% 6% 5
Slide 15: Share Information and Shareholder Structure
Share Information and Shareholder Structure Stable shareholder structure (KRKG SV) Average daily turnover and stock price YTD Shareholder structure as of 30 September 2025 1.600 1490 225 1.400 200 1.200 18.3% EUR thousand 1.000 175 759 800 653 667 150 519 41.7% 600 125 7.1% 400 100 200 75 0 2021 202
Slide 16: Sustainability Governance of the Krka Group
Sustainability Governance of the Krka Group CSRD/ESRS reporting requirements implementation Material ESG Topic Groups Key Activities ACCESSIBLE HEALTHCARE ✓ Implemented CSRD/ESRS requirements published within 2024 Annual report released on 10 April 2025 PRODUCT QUALITY & PATIENT SAFETY ✓ Continuousl
Slide 17: 2025 Estimate and 2026 Guidance
2025 Estimate and 2026 Guidance Guidance in line with strategic goals Sales Net income (EUR million) (EUR million) 2025 Estimate +5.5% 2,132 +5.7% 405 +5.8 % 2.020 383 Sales: EUR 2,020 million +7.5% 1.910 356 Net Income: EUR 383 million 2024 2025-estimate 2026-guidance 2024 2025-estimate 2026-guidan
Slide 18: Krka Group Development Strategy 2026-2030
Where Access and Agility Lead… KRKA GROUP DEVELOPMENT STRATEGY 2026-2030 ...Value Follows
Slide 19: Krka Group Development Strategy 2026-2030
Krka Group Development Strategy 2026-2030 Strategic guidelines Generic pharmaceutical market has entered a new mature phase — the ability to ensure adequate product quantities is becoming an increasingly important competitive advantage — no longer just the focus on new products and patent expiration
Slide 20: Krka Group Development Strategy 2026-2030
Krka Group Development Strategy 2026-2030 Amplifying our strategic foundation built on three strategic pillars PROVIDING VERTICAL INTEGRATION VALUE CREATION ACCESS TO MEDICINES We supply! We leverage! We create! Providing uninterrupted and sufficient Ensuring sufficient quantities of Positive impact
Slide 21: Krka Group Development Strategy 2026-2030
Krka Group Development Strategy 2026-2030 Ensure uninterrupted supply of sufficient Ensure the sufficient quantities of Ensure that the positive impacts of our quantities of high-quality, safe, and products, and further strategically operations reach all stakeholders, and effective medicines strengt
Slide 22: Summary: key strategic objectives
Krka Group Development Strategy 2026-2030 Summary: key strategic objectives To achieve Annual sales revenue allocated ≥ 5% Average annual sales growth 10% to R&D > 25% Average EBITDA margin Strengthen our position among the Average annual CAPEX allocated Net profit of majority shareholders Top 5 top
Slide 23: Disclaimer
Disclaimer The information, statements or data contained in this presentation has been prepared by Krka, tovarna zdravil, d. d., Novo mesto (hereinafter: the Company) and has been prepared solely for the purpose of informative presentation of the Company business operations. The presentation is not
Slide 24: Living a healthy life.
Living a healthy life.
Krka, d. d., Novo mesto — Investor Day (November 2025) on 6ix